Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an...
An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has...
The Therapeutics Discovery division at MD Anderson Cancer Center has advanced a new small-molecule inhibitor of cancer metabolism to...
Through in-depth retrospective analysis of data from more than 36,000 patients, a new study led by researchers at The University of...
Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many...
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and...
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in...
MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1...
Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes...
Lymphomas are the most common hematological malignancy in the U.S., accounting for an estimated 80,000 new cancer diagnoses and 21,000...